28 October 2020
The World Health Organization (WHO) announced in this week’s WHO Weekly Epidemiological Record that Malawi has been validated to have eliminated lymphatic filariasis as a public health problem.
This research article, co-authored by MDP’s Yao Sodahlon and Joni Lawrence, Merck’s Rachel Taylor, The Task Force for Global Health’s CEO, Dave Ross, and many NTD program managers, is focused on the need for building country capacity by increasing country ownership and domestic spending for NTD programs.
Sodahlon et al., 2020 (453.99 KB)
A recent study informed that ivermectin was successfully used in vitro for the treatment of SARS-CoV-2 in experimentally infected cells and two preprint publications on observational clinical studies reported the apparent utility of ivermectin to treat patients with COVID-19 needing mechanical ventilation; neither of these studies were peer-reviewed nor formally published and one of them was later retracted.
PAHO Recommendation Regarding the Use of Ivermectin as a Treatment for COVID-19 (381.44 KB)
The Mectizan Donation Program is committed to working towards WHO’s NTD Road Map 2030 targets and the path towards eliminating river blindness and lymphatic filariasis.
This short film covers the dedication of a community drug distributor on working towards eliminating onchocerciasis (river blindness) in Cameroon, Africa.
This research article is focused on the mapping of lymphatic filariasis (LF) in Loa loa endemic health districts in forest areas of Cameroon.
Beng et al., 2020 (1.68 MB)
This research article focuses on the results of four rounds of mass drug administration (MDA) for cross-border districts of Côte d’Ivoire where lymphatic filariasis (LF) is endemic.
Yokoly et al., 2020 (1.05 MB)
In order to confirm that transmission recrudescence or importation does not occur for lymphatic filariasis (LF) after mass drug administration (MDA), the WHO recommends post-treatment surveillance.
Eigege et al., 2020 (321.96 KB)
This research article examines the Ov16 (onchocerciasis) and Wb123 (lymphatic filariasis) seroprevalence in the Bakoye and Falémé foci in Mali after 24 – 25 years of treatment.
Dolo et al., 2020 (1.05 MB)
This short film covers the movement to eliminate Onchocerciasis (river blindness) in Cameroon, Africa. Follow our Vimeo account for more video footage from the field.
This editorial from Darin S. Evans raises important questions regarding the decision to stop mass drug administration (MDA) for countries with onchocerciasis as they approach transmission interruption.
Evans, 2020 (38.33 KB)
The WHO road map for neglected tropical diseases (NTDs) is a call to action for Member States, donors, implementing partners, disease experts and all other stakeholders to align their strategies and plans towards the prevention of infections and alleviation of the suffering of people affected by NTDs.
WHO Road Map for NTDs 2021-2030 (2.45 MB)
This research paper focuses on the first stop-Mass Drug Administration (MDA) decision for onchocerciasis in Nigeria. These findings can be modeled by other African countries to advance their MDA programs to reach similar levels of success.
Richards et al., 2020 (803.37 KB)
This research paper details the coordinated stop of MDA, decided by Sudan and Ethiopia, due to satisfying the World Health Organization’s criteria for interruption of onchocerciasis transmission.
Katabarwa et al., 2020 (3.04 MB)